GSK Expands Lupus Portfolio with $300M Upfront Deal for T-Cell Engager

Deal Details:
GlaxoSmithKline (GSK) has entered into a deal with Chimagen Biosciences to acquire a clinical-stage T-cell engager, CMG1A46, for $300 million upfront. The deal could potentially reach $850 million with additional biobucks.

Target Indications:
The T-cell engager is aimed at treating systemic lupus erythematosus (SLE) and lupus nephritis, with potential expansion to other B-cell-driven autoimmune diseases.

Mechanism of Action:
CMG1A46 is a dual CD19- and CD20-targeted T-cell engager designed to achieve deep B-cell depletion with lower toxicity compared to traditional T-cell engagers.

Clinical Status:
The candidate is currently in Phase 1 trials for leukemia and lymphoma but will be repurposed for lupus and related autoimmune conditions.

Strategic Impact:
This deal aims to extend GSK’s dominance in the lupus market, building on the success of its existing lupus drug, Benlysta.